ProQR Therapeutics (PRQR) Cash & Current Investments (2013 - 2025)

ProQR Therapeutics has disclosed Cash & Current Investments across 13 years of filings, most recently posting $107.6 million for Q4 2025.

• Cash & Current Investments for Q4 2025 came in at $107.6 million, down 32.62% year-over-year; the trailing twelve-month figure through Dec 2025 was $107.6 million (down 32.62% YoY), and the FY2025 annual result was $107.6 million, down 32.62% from the prior year.
• Cash & Current Investments came in at $107.6 million for Q4 2025 at ProQR Therapeutics, down from $174.7 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $219.1 million in Q4 2021 to a low of $91.5 million in Q1 2021.
• The 5-year median for Cash & Current Investments is $146.0 million (2023), against an average of $147.4 million.
• Peak annual rise in Cash & Current Investments reached 139.65% in 2021, while the deepest fall reached 99.93% in 2021.
• ProQR Therapeutics' Cash & Current Investments stood at $219.1 million in 2021, then tumbled by 55.28% to $98.0 million in 2022, then soared by 30.59% to $128.0 million in 2023, then increased by 24.77% to $159.7 million in 2024, then slumped by 32.62% to $107.6 million in 2025.
• The last three Cash & Current Investments figures came in at $107.6 million (Q4 2025), $174.7 million (Q3 2025), and $169.1 million (Q2 2025), per Business Quant data.